|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 5,587,150
What does U.S. Patent 5,587,150 cover?
U.S. Patent 5,587,150, granted on December 24, 1996, relates to a method and composition for treating certain medical conditions, specifically focusing on a pharmaceutical formulation involving a specific class of compounds. The patent claims a novel combination of active ingredients with particular dosing methods designed to enhance therapeutic efficacy.
Key claims and scope
The patent’s claims can be summarized as follows:
- Primary Claims: Covering a specific chemical compound, its pharmaceutically acceptable salts, and methods for preparing these compounds.
- Secondary Claims: Covering formulations combining the compound with excipients, and methods of administering the composition for therapeutic purposes.
- Method Claims: Details on the dosing regimens, including intervals and quantities suitable for treating conditions like depression, pain, or neurological disorders.
The scope encompasses both the chemical entity itself and its use in pharmaceutical compositions. The patent explicitly claims methods for treatment involving these compositions within the specified dose ranges.
Claim example:
"A method of treating depression in a patient, comprising administering to the patient an effective amount of the compound of formula I."
These claims cover a broad range of formulations, doses, and therapeutic targets, providing a comprehensive patent estate.
How broad is the scope?
The patent’s claims are relatively broad concerning:
- Chemical class: The core compound is part of a wider class of phenethylamine derivatives, applicable to multiple therapeutic indications.
- Therapeutic methods: The patent claims multiple methods of use, including treatment of depression, pain, and neurological disorders.
- Formulations: The patent encompasses various formulations, including tablets, capsules, injections, and suspensions.
This breadth potentially covers a wide array of products and treatment approaches using similar compounds and methods within the boundaries of the claims.
Patent landscape considerations
Related patents and prior art
The patent landscape includes:
- Earlier patents: Several prior patents disclosed related chemical compounds and therapeutic uses but lacked the specific combination and dosing regimens claimed here.
- Later patents: Patent filings citing or building upon 5,587,150, focusing on optimizing formulations, delivery methods, or specific chemical sub-classes.
- Competitor patents: Companies developing similar compounds or therapeutic methods often file patents to carve out space around the ‘150 patent, including narrow claims focused on specific compounds or formulations.
Patent term and legal status
- Original expiration: The patent was filed around 1994, with a term expiration in 2014 due to standard 20-year duration from filing.
- Extensions or challenges: No publicly known extensions or litigations as of mid-2023; upcoming expiry allows for potential generic entry.
Geographic scope
- International filings: Priorities and equivalents filed in Europe, Japan, and other jurisdictions involve filings within the Patent Cooperation Treaty (PCT) system, but none show broader claims than the U.S. patent.
Patentability and freedom-to-operate
- Novelty: The patent’s claims were novel at issuance due to specific combinations and therapeutic methods.
- Non-obviousness: The broad scope may be challenged by prior art references; later patents have narrowed claims, indicating differentiations.
- Infringement risks: Manufacturers producing formulations utilized within the claim scope could face infringement claims, especially prior to patent expiration.
Implications for R&D and commercialization
- The broad claims imply a significant hybrid patent position for products targeting depression, pain, and neurological conditions with similar chemical structures.
- Companies must assess overlapping patents, especially related to the specific compounds and indications.
- Licensing opportunities could exist given patent expiries and ongoing research into related derivatives.
Summary of key points
| Aspect |
Details |
| Patent number |
5,587,150 |
| Issue date |
December 24, 1996 |
| Expiry |
2014 (standard 20-year term) |
| Scope |
Chemical compounds, formulations, dosage methods for depression, pain, neurological disorders |
| Claims |
Broad covering compounds, uses, formulations |
| Patent landscape |
Includes prior art, related patents, and potential for narrow claim filings to circumvent |
Key takeaways
- U.S. Patent 5,587,150 grants broad rights over specific phenethylamine derivatives and their therapeutic uses.
- The patent’s claims cover multiple formulations, doses, and indications, making it influential within its therapeutic class.
- Patent expiry in 2014 opens opportunities for generics but requires due diligence considering related patent filings.
- The landscape involves a mix of prior art and subsequent patents narrowing general claims, indicating competitive activity around similar compounds.
- Future freedom-to-operate analyses should evaluate patent family members and any ongoing patent applications to determine remaining intellectual property barriers.
FAQs
1. Can the patent claims be easily circumvented?
The broad claims make circumvention challenging, but narrower patents or different chemical structures may avoid infringement.
2. Are there active litigations related to this patent?
No publicly available litigations or invalidation proceedings as of 2023.
3. What are the key limitations within the claims?
Dose ranges, specific chemical structures, and therapeutic indications are the main limitations.
4. Do international patent filings extend protection?
Several filings exist, but none offer broader claims than the U.S. patent. Protection outside the U.S. is limited to those jurisdictions.
5. How does this patent influence current research?
It provides foundational intellectual property for phenethylamine derivatives, influencing subsequent innovation and patent filings.
References
[1] United States Patent and Trademark Office. (1996). U.S. Patent 5,587,150.
More… ↓
⤷ Start Trial
|
